Arcturus Therapeutics Q2 2024 Earnings Report
Key Takeaways
Arcturus Therapeutics reported a revenue of $49.9 million for the second quarter of 2024, a significant increase of $39.4 million compared to the same period in 2023. The net loss for the quarter was $17.2 million, or ($0.64) per diluted share, compared to a net loss of $52.6 million, or ($1.98) per diluted share in the second quarter of 2023.
Revenues increased to $49.9 million, up from $10.5 million in the same period last year, primarily due to the CSL agreement and advancements in the pandemic flu program.
Total operating expenses were $71.0 million, compared to $65.9 million for the three months ended June 30, 2023.
Net loss was $17.2 million, or ($0.64) per diluted share, compared to a net loss of $52.6 million, or ($1.98) per diluted share in the same period last year.
Cash, cash equivalents, and restricted cash totaled $317.2 million as of June 30, 2024.